{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:18:29Z","timestamp":1795141109220,"version":"4.10.3"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"name":"Research to Prevent Blindness","award":["GR004596-1"],"award-info":[{"award-number":["GR004596-1"]}],"id":[{"id":"https:\/\/ror.org\/04drjs621","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report the rates, culture results, and visual acuity outcomes of endophthalmitis after intravitreal injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective, consecutive case series of all patients who underwent intravitreal injection at University of Miami\u2014Bascom Palmer Eye Institute between January 1, 2021, and December 31, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Endophthalmitis occurred following intravitreal injection in 3\/28,358 (0.011%) eyes in 2021, 3\/24,918 (0.012%) in 2022, 3\/24,840 (0.012%) in 2023, 1\/28,831 (0.003%) in 2024, and 0\/31,269 in 2025 (0%). The use of ranibizumab decreased with time in the current study while faricimab usage increased. There was a slight increase in aflibercept usage after the approval of high dose 8 mg aflibercept in 2023. Complement inhibitors pegcetacoplan and avacincaptad pegol, approved in 2023 for geographic atrophy, were administered in 1,894 and 423 eyes, respectively, in 2024, and 1,083 and 578 eyes, respectively, in 2025; no cases of endophthalmitis were associated with either agent. Vitreous cultures demonstrated growth of\n                      <jats:italic toggle=\"yes\">Streptococcus mitis\/oralis<\/jats:italic>\n                      in 1\/10 (10%),\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      in 1\/10 (10%),\n                      <jats:italic toggle=\"yes\">Granulicatella adiacens<\/jats:italic>\n                      in 1\/10 (10%),\n                      <jats:italic toggle=\"yes\">Staphylococcus epidermis<\/jats:italic>\n                      in 1\/10 (10%),\n                      <jats:italic toggle=\"yes\">Abiotrophia defectiva<\/jats:italic>\n                      in 1\/10 (10%), and were negative in 5\/10 (50%). The cumulative incidence of endophthalmitis over the 5-year time period was 0.0072% (10\/138,216) and was similar to rates reported between 2005 and 2020 at the same institution (P = 0.18). There were no differences in the rates of endophthalmitis between various medications (P = 0.32). After treatment, mean best-corrected visual acuity at last follow-up examination was 1.42 logMAR (20\/526; range: 20\/20 to no light perception).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Endophthalmitis is a rare complication of intravitreal injection. In this study, the incidence of endophthalmitis was similar to previously reported rates and did not differ between agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004855","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:31Z","timestamp":1776351631000},"page":"1486-1491","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTION"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-421X","authenticated-orcid":false,"given":"Landon J.","family":"Rohowetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smiddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Yannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-7467","authenticated-orcid":false,"given":"Harry W.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Endophthalmitis Injection Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00210-019-01629-y","article-title":"A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach","volume":"392","author":"Yeung","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3928\/23258160-20180501-04","article-title":"Endophthalmitis associated with intravitreal injections of anti-VEGF agents at a tertiary referral center: in-house and referred cases","volume":"49","author":"Yannuzzi","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/OPTH.S169143","article-title":"Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis","volume":"12","author":"Kiss","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3928\/23258160-20240627-01","article-title":"RWC update: removal of a dislocated ganciclovir implant; the role of early vitrectomy for endophthalmitis; inherited retinal disease","volume":"55","author":"Sharma","year":"2024","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2015.04.013","article-title":"Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome","volume":"160","author":"Dossarps","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J Refract Surg"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3928\/23258160-20210528-04","article-title":"Trends in endophthalmitis associated with intravitreal injection of anti-VEGF agents at a tertiary referral center","volume":"52","author":"Reyes-Capo","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3928\/23258160-20140306-08","article-title":"Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"45","author":"Fileta","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R11-20261120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/ICB.0000000000000925","article-title":"Case report of Abiotrophia defectiva endophthalmitis after repeated injections of dexamethasone intravitreal implant (Ozurdex)","volume":"16","author":"Cruz-I\u00f1igo","year":"2022","journal-title":"Retin Cases Brief Rep"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"acmi000124","DOI":"10.1099\/acmi.0.000124","article-title":"Abiotrophia defectiva endophthalmitis following routine cataract surgery: the first reported case in the United Kingdom","volume":"2","author":"Chihaia","year":"2020","journal-title":"Access Microbiol"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/JCM.37.5.1564-1566.1999","article-title":"Abiotrophia species as a cause of endophthalmitis following cataract extraction","volume":"37","author":"Namdari","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10096-010-0901-7","article-title":"Abiotrophia defectiva endophthalmitis with retinal involvement and infiltrative keratitis: case report and review of the literature","volume":"29","author":"Horstkotte","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/24741264231191339","article-title":"Impact of prefilled syringes and masking on postintravitreal injection endophthalmitis","volume":"7","author":"Louis","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"R16-20261120","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/jcm14072491","article-title":"Comparison of endophthalmitis rates between prefilled syringes and standard vials in aflibercept intravitreal injections: a retrospective study in Japan","volume":"14","author":"Morioka","year":"2025","journal-title":"J Clin Med"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","article-title":"The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab","volume":"199","author":"Storey","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R18-20261120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.oret.2025.08.006","article-title":"Rates of endophthalmitis in prefilled versus nonprefilled syringes for intravitreal injections: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000001583","article-title":"Pooled estimates of incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents with and without topical antibiotic prophylaxis","volume":"38","author":"Reibaldi","year":"2018","journal-title":"Retina"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.oret.2018.09.013","article-title":"Predictors of endophthalmitis after intravitreal injection: a multivariable analysis based on injection protocol and povidone iodine strength","volume":"3","author":"Stem","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R21-20261120","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/IAE.0b013e3182877585","article-title":"Povidone-iodine contact time and lid speculum use during intravitreal injection","volume":"33","author":"Friedman","year":"2013","journal-title":"Retina"},{"key":"R22-20261120","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41433-020-01145-x","article-title":"Post-injection endophthalmitis rates with reduced povidone-iodine prophylaxis in patients with self-reported iodine sensitivity","volume":"35","author":"Mulcahy","year":"2021","journal-title":"Eye (Lond)"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:00:25Z","timestamp":1795140025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004855"}},"subtitle":["Rates, Culture Results, and Visual Acuity Outcomes"],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004855","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}